Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 20;41(2):e70068.
doi: 10.1002/joa3.70068. eCollection 2025 Apr.

Prophylactic implantation of cardioverter-defibrillator in patients with advanced light-chain amyloidosis-A pilot study

Affiliations

Prophylactic implantation of cardioverter-defibrillator in patients with advanced light-chain amyloidosis-A pilot study

Hui-Qiang Wei et al. J Arrhythm. .

Abstract

Background: Ventricular arrhythmias (VAs) and electromechanical dissociation have been observed as the most common causes of sudden cardiac death (SCD) in patients with light chain (AL) amyloidosis. However, an implantable cardioverter-defibrillator (ICD) has rarely been implanted in patients with advanced AL amyloidosis due to very poor prognosis.

Methods: Between July 2021 and December 2022, 10 patients with advanced cardiac AL amyloidosis referred to our institute who received prophylactic ICD implantation were prospectively recruited. The primary endpoint was the prevalence of VAs and appropriate ICD therapies determined by ICD interrogation. The secondary endpoint was all-cause mortality during the follow-up period.

Results: During a mean follow-up of 12.1 ± 4.4 months, sustained ventricular tachycardia (VT)/ventricular fibrillation (VF) occurred in 4 of 10 (40%) patients. One patient had spontaneous termination of VT before the delivery of ICD therapy, and the remaining 3 patients had ICD therapies used, either ATP or shock. Inappropriate shock was not recorded in any patients. Patients with sustained VT/VF had wider QRS duration (143 ± 41 vs. 99 ± 10 ms, p = 0.03) and a higher incidence of bundle branch block (BBB)/interventricular conduction delay (IVCD) (75% vs. 0%, p = 0.01) compared to those without.

Conclusion: VAs are commonly observed among patients with advanced AL amyloidosis, and ICD therapy can be effective in successfully treating sustained VA in these patients. On the basis of our preliminary data, prophylactic ICD implantation may be proposed to the advanced AL amyloidosis to improve the survival rate in selected patients with advanced AL amyloidosis, especially for the patients with wider QRS duration and BBB/IVCD.

Keywords: amyloidosis; implantable cardioverter‐defibrillator; survival; ventricular arrhythmia.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflict of interests for this article.

Figures

FIGURE 1
FIGURE 1
Flowchart of consecutive patients with advanced light chain cardiac amyloidosis enrolled in this study. AL, light chain; ICD, implantable cardioverter‐defibrillator; VA, ventricular arrhythmia. ICD treatment was successful in the majority of patients. Patients with wider QRS duration and RBBB/IVCD were more likely to experience sustained VAs. A higher level of hs‐cTnT and wider QRS duration were significantly associated with mortality in patients with advanced AL amyloidosis. Hs‐cTnT, high‐sensitivity cardiac Troponin T; ICD, implantable cardioverter‐defibrillator; IVCD, interventricular conduction delay; RBBB, right bundle branch block; VA, ventricular arrhythmia.

Similar articles

Cited by

References

    1. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047–2060. - PubMed
    1. Sabinot A, Ghetti G, Pradelli L, Bellucci S, Lausi A, Palladini G. State‐of‐the‐art review on al amyloidosis in western countries: epidemiology, health economics, risk assessment and therapeutic management of a rare disease. Blood Rev. 2023;59:101040. - PubMed
    1. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light‐chain (al) amyloidosis with heart involvement. QJM. 1998;91(2):141–157. 10.1093/qjmed/91.2.141 - DOI - PubMed
    1. Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, et al. Prophylactic implantation of cardioverter‐defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008;5:235–240. - PubMed
    1. Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH. Electrophysiologic abnormalities in al (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30:1046–1051. - PubMed

LinkOut - more resources